Peptide lexicon
Mazdutid
Oxyntomodulin analogue acting at the glucagon and GLP-1 receptors (LY3305677 / IBI362).
| Substance class | Peptide |
|---|---|
| CAS number | 2259884-03-0 |
| Molecular formula | C₂₀₇H₃₁₇N₄₅O₆₅ |
| Molar mass | 4,476 g/mol |
| Synonyms | LY3305677, IBI362, Glukagon/GLP-1-Dual-Agonist |
| PubChem | CID 167312357 |
Structure
Mazdutide is a lipidated peptide modelled on oxyntomodulin, a gut hormone that activates both receptors. Its fatty-acid side chain allows weekly administration in clinical protocols.
State of research
Published work mainly covers body weight, glucose metabolism and liver fat; preclinically, the contribution of glucagon-receptor activation to energy expenditure is studied.
Status
Mazdutide is not approved as a medicinal product in the EU.
Literature
- Emerging pharmacotherapies for obesity: A systematic reviewPharmacol Rev, 2025 · PMID 39952695 · DOI 10.1124/pharmrev.123.001045
- Mazdutide: First ApprovalDrugs, 2025 · PMID 41028652 · DOI 10.1007/s40265-025-02249-y
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysisBMJ, 2026 · PMID 42419792 · DOI 10.1136/bmj-2026-372161
- Beyond weight loss: multisystem benefits of obesity medicationsLancet Diabetes Endocrinol, 2026 · PMID 42208956 · DOI 10.1016/S2213-8587(26)00100-2
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trialsMetabolism, 2024 · PMID 39305981 · DOI 10.1016/j.metabol.2024.156038
